losartan has been researched along with Weight Gain in 11 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The AT(1) receptor for angiotensin II (Ang II) is involved in the renal expression of the nuclear factor-kappa B (NF-ΚB) during this nephrosis." | 7.77 | Proinflammatory role of angiotensin II in a rat nephrosis model induced by adriamycin. ( Hernández-Fonseca, JP; Mosquera, J; Muñoz, M; Pedreañez, A; Rincón, J; Viera, N, 2011) |
| "To study the effect of losartan, an angiotensin II antagonist, on bleomycin-induced pulmonary fibrosis in rats and its possible mechanism." | 7.73 | Losartan attenuates bleomycin-induced pulmonary fibrosis in rats. ( Lu, Y; Yao, HW; Zhao, MH; Zhu, JP, 2006) |
| " The AT(1) receptor for angiotensin II (Ang II) is involved in the renal expression of the nuclear factor-kappa B (NF-ΚB) during this nephrosis." | 3.77 | Proinflammatory role of angiotensin II in a rat nephrosis model induced by adriamycin. ( Hernández-Fonseca, JP; Mosquera, J; Muñoz, M; Pedreañez, A; Rincón, J; Viera, N, 2011) |
| "To study the effect of losartan, an angiotensin II antagonist, on bleomycin-induced pulmonary fibrosis in rats and its possible mechanism." | 3.73 | Losartan attenuates bleomycin-induced pulmonary fibrosis in rats. ( Lu, Y; Yao, HW; Zhao, MH; Zhu, JP, 2006) |
| "Telmisartan is an angiotensin II receptor blocker and selective modulator of peroxisome proliferator-activated receptor-gamma reported to increase energy expenditure and improve glucose and lipid metabolism compared with other angiotensin II receptor blockers." | 1.35 | Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-gamma dependent pathway. ( Hyakukoku, M; Kazdová, L; Kren, V; Kurtz, TW; Pravenec, M; Qi, NR; Simáková, M; Sugimoto, K; Zídek, V, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| do Carmo, JM | 1 |
| Dai, X | 1 |
| Aitken, N | 1 |
| Larson, KM | 1 |
| Omoto, ACM | 1 |
| Gulke, RR | 1 |
| Wang, Z | 1 |
| Li, X | 1 |
| Mouton, AJ | 1 |
| Hall, JE | 1 |
| da Silva, AA | 1 |
| Karimi, J | 1 |
| Mohammadalipour, A | 1 |
| Sheikh, N | 1 |
| Khodadadi, I | 1 |
| Hashemnia, M | 1 |
| Goudarzi, F | 1 |
| Khanjarsim, V | 1 |
| Solgi, G | 1 |
| Hajilooi, M | 1 |
| Bahabadi, M | 1 |
| Kheiripour, N | 1 |
| Hedayatyanfard, K | 1 |
| Muñoz, M | 1 |
| Rincón, J | 1 |
| Pedreañez, A | 1 |
| Viera, N | 1 |
| Hernández-Fonseca, JP | 1 |
| Mosquera, J | 1 |
| Gupte, M | 1 |
| Thatcher, SE | 1 |
| Boustany-Kari, CM | 1 |
| Shoemaker, R | 1 |
| Yiannikouris, F | 1 |
| Zhang, X | 1 |
| Karounos, M | 1 |
| Cassis, LA | 1 |
| Ashrafi, F | 1 |
| Nematbakhsh, M | 1 |
| Safari, T | 1 |
| Talebi, A | 1 |
| Nasri, H | 1 |
| Khazaei, M | 1 |
| Baradaran-Mahdavi, MM | 1 |
| Jafapisheh, A | 1 |
| Olia, B | 1 |
| Pirhaji, O | 1 |
| Hashemi-Nia, SJ | 1 |
| Eshraghi, F | 1 |
| Pezeshki, Z | 1 |
| Mortazavi, M | 1 |
| Benson, SC | 1 |
| Pershadsingh, HA | 1 |
| Ho, CI | 1 |
| Chittiboyina, A | 1 |
| Desai, P | 1 |
| Pravenec, M | 2 |
| Qi, N | 1 |
| Wang, J | 1 |
| Avery, MA | 1 |
| Kurtz, TW | 2 |
| Yao, HW | 1 |
| Zhu, JP | 1 |
| Zhao, MH | 1 |
| Lu, Y | 1 |
| Sugimoto, K | 1 |
| Kazdová, L | 1 |
| Qi, NR | 1 |
| Hyakukoku, M | 1 |
| Kren, V | 1 |
| Simáková, M | 1 |
| Zídek, V | 1 |
| Zanchi, A | 1 |
| Schaad, NC | 1 |
| Osterheld, MC | 1 |
| Grouzmann, E | 1 |
| Nussberger, J | 1 |
| Brunner, HR | 1 |
| Waeber, B | 1 |
| Schneider, AW | 1 |
| Kalk, JF | 1 |
| Klein, CP | 1 |
| Shimada, N | 1 |
| Hayashi, K | 1 |
| Saka, S | 1 |
| Nakamura, T | 1 |
| Ebihara, I | 1 |
| Koide, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Placebo Controlled, Double Blind Trial of Telmisartan in Hypertensive, Obese Adolescents[NCT00185705] | 30 participants (Anticipated) | Interventional | 2006-10-31 | Terminated (stopped due to Primary investigator moved to different university) | |||
| Molecular - Genetic Alterations in Adipose Tissue After Change in Therapy From ACE Inhibitors to AT1 Receptor Blockers in Patients With Essential Hypertension[NCT01444833] | 35 participants (Anticipated) | Interventional | 2008-10-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for losartan and Weight Gain
| Article | Year |
|---|---|
Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Bilirubin; Female; Hemodynam | 1999 |
10 other studies available for losartan and Weight Gain
| Article | Year |
|---|---|
Sex differences in weight gain, blood pressure control, and responses to melanocortin-4 receptor antagonism in offspring from lean and obese parents.
Topics: Adrenergic Agents; Adult; Blood Pressure; Female; Humans; Hypertension; Losartan; Male; Obesity; Rec | 2023 |
Protective effects of combined Losartan and Nilotinib on carbon tetrachloride (CCl
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Carbon Tetrachloride; Drug Therapy, Combination; L | 2020 |
Proinflammatory role of angiotensin II in a rat nephrosis model induced by adriamycin.
Topics: Angiotensin II; Animals; Cholesterol; Disease Models, Animal; Doxorubicin; Endothelin-1; Fluorescent | 2011 |
Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL/6 mice.
Topics: 3T3-L1 Cells; Adipocytes; Adiposity; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor B | 2012 |
A combination of vitamin C and losartan for cisplatin-induced nephrotoxicity in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Ascorbic Acid; Biomarkers; Blood Pro | 2012 |
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Co | 2004 |
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Co | 2004 |
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Co | 2004 |
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Co | 2004 |
Losartan attenuates bleomycin-induced pulmonary fibrosis in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antibiotics, Antineoplastic; Bleomycin; Body Weigh | 2006 |
Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-gamma dependent pathway.
Topics: Adiposity; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Fatty Acids; | 2008 |
Effects of chronic NO synthase inhibition in rats on renin-angiotensin system and sympathetic nervous system.
Topics: Amino Acid Oxidoreductases; Analysis of Variance; Animals; Antihypertensive Agents; Arginine; Biphen | 1995 |
Does angiotensin II receptor antagonist Losartan suppress drinking behavior in hemodialysis patients?
Topics: Aged; Drinking Behavior; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kidney Fai | 2001 |